Can We Predict Individual Combined Benefit and Harm of Therapy? Warfarin Therapy for Atrial Fibrillation as a Test Case.
To construct and validate a prediction model for individual combined benefit and harm outcomes (stroke with no major bleeding, major bleeding with no stroke, neither event, or both) in patients with atrial fibrillation (AF) with and without warfarin therapy.Using the Kaiser Permanente Colorado datab...
Main Authors: | Guowei Li, Lehana Thabane, Thomas Delate, Daniel M Witt, Mitchell A H Levine, Ji Cheng, Anne Holbrook |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4981352?pdf=render |
Similar Items
-
Warfarin therapy in atrial fibrillation: assessment of patient knowledge of risks and benefits
by: P. Fitzgerald, et al.
Published: (2020-05-01) -
Rates of hemorrhage during warfarin therapy for atrial fibrillation
by: S.A. Punekar, et al.
Published: (2014-11-01) -
Initiation and Persistence with Warfarin Therapy in Atrial Fibrillation According to Ethnicity
by: Carolina eMalta Hansen, et al.
Published: (2012-06-01) -
Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
by: Antonio de Padua Mansur, et al.
Published: (2012-01-01) -
Warfarin therapy in patients with coronary heart disease and atrial fibrillation: drug interactions and genetic sensitivity to warfarin
by: O. A. Panibratiuk, et al.
Published: (2020-06-01)